AzTrials
AzTrials

Bowel PreparationEarly Phase 1NCT07127237

Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults

A Early Phase 1 study testing Bisacodyl 5 MG and Prucalopride 2mg in people with Bowel Preparation, run by Hospital de Clínicas Dr. Manuel Quintela.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of this randomized clinical trial is to compare prucalopride versus bisacodyl as a stimulant agent for bowel cleansing preparation prior to colonoscopy in patients undergoing the procedure at the Endoscopy Unit of the Hospital de Clínicas. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Bowel Preparation
What is being tested?
Bisacodyl 5 MG and Prucalopride 2mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
124 participants
Where
No sites listed yet
Study dates
Sep 2025to Feb 2026
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • All patients over 18 years of age.
  • Without prior colonic surgical interventions.
  • Who attend the Digestive Endoscopy service to undergo a colonoscopy.

Who cannot join

  • Patients who voluntarily choose not to participate in the study.
  • Pregnant women.
  • Patients with rectocolonic resections and/or ileostomies.
  • Inflammatory bowel disease.
  • Inadequate bowel preparation in a previous colonoscopy.
  • Suspected intestinal obstruction or perforation.
Show all 19Show fewer
  • Intestinal intussusception.
  • Melena.
  • Oral iron intake within the last 10 days.
  • Emergency colonoscopies.
  • Hypersensitivity to any component of the bowel preparation solutions.
  • Chronic kidney disease on dialysis.
  • Uncorrected severe electrolyte imbalances.
  • Major psychiatric disorders.
  • Low intellectual quotient.
  • Severe constipation (≤ 1 bowel movement per week).
  • Chronic diarrhea with high frequency (≥ 4 daily bowel movements of uniformly decreased consistency for more than 4 weeks).
  • Decompensated cardiac diseases (ischemic heart disease, congestive heart failure, unstable angina, arrhythmias, and uncontrolled hypertension).
  • Ascites.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Prucaloprida vs Bisacodyl as a Stimulant in Bowel Preparation for Video Colonoscopy in Adults: A Randomized Clinical Trial

The objective of this randomized clinical trial is to compare prucalopride versus bisacodyl as a stimulant agent for bowel cleansing preparation prior to colonoscopy in patients undergoing the procedure at the Endoscopy Unit of the Hospital de Clínicas. The main research questions this study aims to answer are:

Is prucalopride superior or equivalent to bisacodyl as a stimulant agent for bowel cleansing preparation before colonoscopy? Is the tolerability of prucalopride better, equivalent, or worse compared to bisacodyl? The investigators will compare the standard bowel cleansing preparation using polyethylene glycol (PEG) in combination with either bisacodyl or prucalopride as the stimulant agent.

Participants will be randomized into two groups, both receiving the same base preparation with different stimulant agents.

Read the detailed description

An analytical, experimental, prospective study will be conducted, specifically a triple-blind randomized clinical trial (blinding of the endoscopist, investigators, and statistician), comparing a bowel preparation regimen for colonoscopy using prucalopride versus bisacodyl.

Patients referred to the Digestive Endoscopy Unit of the Gastroenterology Department at the Hospital de Clínicas for colonoscopy (VCC) who meet the inclusion criteria will be invited to participate in the study. Referrals will include both hospitalized patients and outpatients from various clinic services.

Statistical Analysis Frequency tables and charts will be used to describe qualitative variables. Measures of central tendency and dispersion (mean ± standard deviation or median and interquartile range [IQR]) will be used for continuous variables depending on the distribution assessed by the Kolmogorov-Smirnov test.

Associations between qualitative variables will be analyzed using the Chi-square test or Fisher's exact test when expected frequencies are less than 5. If a statistically significant association is found, the strength of the association will be expressed using the Relative Risk (RR) and its corresponding 95% Confidence Interval (CI).

Differences between groups in normally distributed continuous variables will be analyzed using the Student's t-test for independent samples, and for non-normally distributed variables, the Mann-Whitney U test will be used.

Adenoma detection rate and cecal intubation rate will be calculated as the number of new cases (detection or cecal intubation) per total number of procedures performed. These rates will be expressed using the appropriate constant K based on the number of patients, along with their 95% CI. The comparison between groups will be performed using a test for comparison of independent proportions. A significance level of α = 0.05 will be established. Statistical analysis will be performed using STATA v.18.0.

Study Variables • Boston Bowel Preparation Scale (BBPS) Conceptual definition: A scale used to assess bowel cleanliness during colonoscopy.

Operational definition:

Score 0: unprepared colon segment with mucosa not visualized due to solid stool that cannot be cleared.

Score 1: portion of mucosa is seen, but other areas are obscured by staining, residual stool, and/or opaque liquid.

Score 2: minor residual staining or small fragments of stool, but mucosa is adequately visualized.

Score 3: entire mucosa is visible with no residual material. Type and scale: Qualitative, ordinal variable.

Categories:

Total score: 0-9. Adequate preparation: BBPS ≥ 2 in each colonic segment. Inadequate preparation: BBPS < 2 in any segment.

  • Tolerance Conceptual definition: Refers to the presence or absence of specific symptoms during bowel preparation, including nausea, vomiting, abdominal pain or distension, headache, dizziness, fatigue, palpitations, and rectal bleeding.

Operational definition:

Good tolerance: ≤ 3 symptoms. Moderate tolerance: 4-5 symptoms. Poor tolerance: ≥ 6 symptoms. Type and scale: Qualitative, ordinal variable. Categories: Good, Moderate, Poor.

  • Overall Adenoma Detection Rate (ADR) Conceptual definition: A quality indicator for colonoscopy. An ADR ≥ 25% is considered acceptable (≥ 30% in men and ≥ 20% in women).

Operational definition: Number of adenomas/adenocarcinomas (confirmed by histology) divided by the total number of colonoscopies performed, multiplied by 100.

Type and scale: Quantitative, continuous variable; ratio scale. Values: 0-100%.

  • Overall Cecal Intubation Rate Conceptual definition: A quality indicator for colonoscopy. Considered acceptable if ≥ 95% in screening colonoscopies and ≥ 90% in other types of colonoscopies.

Operational definition: Number of colonoscopies where the ileocecal valve is visualized divided by the total number of colonoscopies performed, multiplied by 100.

Type and scale: Quantitative, continuous variable; ratio scale. Values: 0-100%.

Data Collection Method Patient Recruitment: All patients scheduled for colonoscopy at the Digestive Endoscopy Unit of the Hospital de Clínicas who meet the inclusion criteria will be invited to participate. Informed consent will be obtained after providing detailed explanations and resolving any questions.

Data Collection Tool: Individual standardized forms with closed-ended questions will be completed for each participant. One of the principal investigators will gather the necessary information to complete the baseline data collection form, including demographic data, medical history, and patient-reported experience with bowel preparation.

Being tested
Bisacodyl 5 MG, Prucalopride 2mg

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bisacodyl 5 MGDrug

    On the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.

  • Prucalopride 2mgDrug

    On the day prior to the procedure, the group receiving prucaloprida will take 1 tablet (2 mg) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.

Study groups in NCT07127237
Study groupRoleWhat they receive
BisacodylExperimentalOn the day prior to the procedure, the group receiving bisacodyl will take 4 tablets (5 mg each) at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation, that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
Receives: Drug: Bisacodyl 5 MG
PrucalopridaExperimentalOn the day prior to the procedure, the group receiving prucalopride will take one 2 mg tablet at 4:00 PM. Subsequently, at 6:00 PM, they will dissolve 3 sachets of PEG in 3 liters of water (1 sachet per liter) and ingest half of the preparation-that is, 1.5 liters over a period of 2 hours. At 10:00 PM, they will ingest the remaining 1.5 liters over another 2-hour period.
Receives: Drug: Prucalopride 2mg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Boston scale

    Scale used to evaluate the quality of bowel preparation during video colonoscopy. Score 0-9; adequate preparation (Boston ≥ 2 points in each colonic segment), inadequate preparation (Boston < 2 points in any of the segments).

    Measured: Periprocedural

Secondary outcomes (3)
  1. Tolerability of bowel preparation. Presence or absence of the following symptoms during bowel preparation: nausea, vomiting, abdominal pain or distension, headache, dizziness, fatigue, palpitations, and rectal bleeding.

    Refers to the presence or absence of the following symptoms during bowel preparation: nausea, vomiting, abdominal pain or distension, headache, dizziness, fatigue, palpitations, and rectal bleeding. Tolerability will be assessed through a standardized questionnaire administered prior to colonoscopy.

    Measured: Periprocedural

  2. Overall adenoma detection rate

    Conceptual definition: A key quality indicator in colonoscopy. An overall adenoma detection rate ≥25% of procedures is considered acceptable (≥30% in men and ≥20% in women).

    Operational definition: Calculated as the number of adenomas/adenocarcinomas (confirmed by histological diagnosis) divided by the total number of colonoscopies performed, multiplied by 100.

    Measured: Until the completion of the studies. Average 1 year

  3. Overall cecal intubation rate

    Conceptual definition: A quality indicator in colonoscopy. An acceptable rate is ≥95% for screening colonoscopies and ≥90% for other types of colonoscopies.

    Operational definition: Calculated as the number of colonoscopies in which the ileocecal valve is visualized, divided by the total number of colonoscopies performed, multiplied by 100.

    Measured: Until the completion of the studies. Average 1 year.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Aug 2025
  2. Study startSep 2025 (estimated)
  3. Primary completionFeb 2026 (estimated)
  4. Study completionFeb 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
124 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07127237
Sponsor's protocol ID
HospitalCDMQ
Status last verified
Jun 2025
First submitted
23 Jun 2025
Last updated
17 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All collected data

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Bisacodyl 5 MG and Prucalopride 2mg in people with Bowel Preparation, run by Hospital de Clínicas Dr. Manuel Quintela.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ignacio Moratorio (+59824871515 ext. 2397, ignacio.moratorio@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Boston scale (time frame: Periprocedural). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in